164 related articles for article (PubMed ID: 12852708)
1. Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes.
Barrett-Connor E; Ensrud KE; Harper K; Mason TM; Sashegyi A; Krueger KA; Anderson PW
Clin Ther; 2003 Mar; 25(3):919-30. PubMed ID: 12852708
[TBL] [Abstract][Full Text] [Related]
2. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.
Barrett-Connor E; Grady D; Sashegyi A; Anderson PW; Cox DA; Hoszowski K; Rautaharju P; Harper KD;
JAMA; 2002 Feb; 287(7):847-57. PubMed ID: 11851576
[TBL] [Abstract][Full Text] [Related]
3. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
Meunier PJ; Vignot E; Garnero P; Confavreux E; Paris E; Liu-Leage S; Sarkar S; Liu T; Wong M; Draper MW
Osteoporos Int; 1999; 10(4):330-6. PubMed ID: 10692984
[TBL] [Abstract][Full Text] [Related]
4. Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia.
Dayspring T; Qu Y; Keech C
Metabolism; 2006 Jul; 55(7):972-9. PubMed ID: 16784972
[TBL] [Abstract][Full Text] [Related]
5. Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women.
Cox DA; Sarkar S; Harper K; Barrett-Connor E
Curr Med Res Opin; 2004 Jul; 20(7):1049-55. PubMed ID: 15265250
[TBL] [Abstract][Full Text] [Related]
6. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Cauley JA; Norton L; Lippman ME; Eckert S; Krueger KA; Purdie DW; Farrerons J; Karasik A; Mellstrom D; Ng KW; Stepan JJ; Powles TJ; Morrow M; Costa A; Silfen SL; Walls EL; Schmitt H; Muchmore DB; Jordan VC; Ste-Marie LG
Breast Cancer Res Treat; 2001 Jan; 65(2):125-34. PubMed ID: 11261828
[TBL] [Abstract][Full Text] [Related]
7. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
[TBL] [Abstract][Full Text] [Related]
8. Raloxifene: a review of its use in postmenopausal osteoporosis.
Clemett D; Spencer CM
Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.
Johnston CC; Bjarnason NH; Cohen FJ; Shah A; Lindsay R; Mitlak BH; Huster W; Draper MW; Harper KD; Heath H; Gennari C; Christiansen C; Arnaud CD; Delmas PD
Arch Intern Med; 2000 Dec 11-25; 160(22):3444-50. PubMed ID: 11112238
[TBL] [Abstract][Full Text] [Related]
10. Carotid artery intima-media thickness after raloxifene treatment.
Mack WJ; Dhungana B; Dowsett SA; Keech CA; Feng M; Li Y; Hodis HN
J Womens Health (Larchmt); 2007 Apr; 16(3):370-8. PubMed ID: 17439382
[TBL] [Abstract][Full Text] [Related]
11. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
12. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.
Walsh BW; Kuller LH; Wild RA; Paul S; Farmer M; Lawrence JB; Shah AS; Anderson PW
JAMA; 1998 May; 279(18):1445-51. PubMed ID: 9600478
[TBL] [Abstract][Full Text] [Related]
13. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
[TBL] [Abstract][Full Text] [Related]
14. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials.
Cohen FJ; Lu Y
Maturitas; 2000 Jan; 34(1):65-73. PubMed ID: 10687884
[TBL] [Abstract][Full Text] [Related]
15. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women.
Anderson PW; Cox DA; Sashegyi A; Paul S; Silfen SL; Walsh BW
Maturitas; 2001 Jul; 39(1):71-7. PubMed ID: 11451623
[TBL] [Abstract][Full Text] [Related]
16. Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial.
Andersson B; Johannsson G; Holm G; Bengtsson BA; Sashegyi A; Pavo I; Mason T; Anderson PW
J Clin Endocrinol Metab; 2002 Jan; 87(1):122-8. PubMed ID: 11788634
[TBL] [Abstract][Full Text] [Related]
17. Serum estradiol level and risk of breast cancer during treatment with raloxifene.
Cummings SR; Duong T; Kenyon E; Cauley JA; Whitehead M; Krueger KA;
JAMA; 2002 Jan; 287(2):216-20. PubMed ID: 11779264
[TBL] [Abstract][Full Text] [Related]
18. Effects of a long-term treatment with raloxifene on insulin sensitivity in postmenopausal women.
Lasco A; Gaudio A; Morabito N; Previti M; Mileto A; Frisina N; Cucinotta D
Diabetologia; 2004 Mar; 47(3):571-574. PubMed ID: 14762655
[TBL] [Abstract][Full Text] [Related]
19. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
Lewin AJ; Kipnes MS; Meneghini LF; Plotkin DJ; Perevozskaya IT; Shah S; Maccubbin DL; Mitchel YB; Tobert JA;
Clin Ther; 2004 Mar; 26(3):379-89. PubMed ID: 15110130
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
Nickelsen T; Creatsas G; Rechberger T; Depypere H; Erenus M; Quail D; Arndt T; Bonnar J;
Climacteric; 2001 Dec; 4(4):320-31. PubMed ID: 11770189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
